secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0001558370-22-007826
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q1 revenue $11.6M (+78% YoY); raises 2022 core revenue guidance to at least 25%
--------------------------------------------------------------------------------

- Total revenue $11.6M, up 78% YoY; core business revenue $9.6M, up 48% YoY driven by cell therapy customers (+57%).
- SPL Program-related revenue $2.0M vs immaterial; total SPLs now 16 with Intima Bioscience addition.
- Net loss narrowed to $4.1M from $7.1M; EBITDA loss $3.7M vs $6.4M.
- Raises 2022 core revenue guidance to at least 25% growth; reiterates SPL milestone revenue ~$4M.
- Cash and investments $246.3M as of March 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837022007826/0001558370-22-007826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837022007826/mxct-20220509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-007826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer